Sharp Therapeutics is engaged in the development of biosensors for cellular biology research and high-throughput screening.
Sharp Therapeutics has raised $972K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Sharp Therapeutics's investors include Innovation Works, STX PARTNERS, Newlin Investment Company, Scott F. Sneddon, Brooks Family Office.
Sharp Therapeutics is headquartered in Pittsburgh, United States.
Sharp Therapeutics is engaged in the development of biosensors for cellular biology research and high-throughput screening.
Sharp Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sharp Therapeutics — Funding & Investors." VCBacked, July 15, 2026, https://www.vcbacked.co/company/sharp-therapeutics. Accessed November 14, 2026.
VCBacked. (2026). Sharp Therapeutics — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/sharp-therapeutics
{{cite web |title=Sharp Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sharp-therapeutics |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Sharp Therapeutics? Request a listing update